"Designing Growth Strategies is in our DNA"

U.S. Treatment-resistant Depression Treatment Market Size, Share & COVID-19 Impact Analysis, By Drug Type (N-Methyl-D-aspartate (NMDA)), Antidepressants, Antipsychotics, and Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Country Forecast, 2023-2030

Last Updated: November 17, 2025 | Format: PDF | Report ID: FBI108772

 

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trend
  4. Key Insights
    1. Prevalence of Treatment-Resistant Depression in the U.S., 2022
    2. Overview of Current Advances in R&D for Antipsychotic Drugs
    3. Pipeline Analysis of Treatment-Resistant Depression Drugs
    4. Key Industry Developments
    5. Impact of COVID-19 on Market
  5. U.S. Treatment-Resistant Depression Treatment Market Analysis, Insights and Forecast, 2019-2030
    1. Market Analysis, Insights and Forecast – By Drug Type
      1. N-Methyl-D-aspartate (NMDA)
      2. Antidepressants
      3. Antipsychotics
      4. Others
    2. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Drug Stores & Retail Pharmacies
      3. Online Pharmacies
  6. Competitive Analysis
    1. U.S. Market Share Analysis (2022)
    2. Company Profiles
      1. Eli Lilly and Company
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      2. GlaxoSmithKline
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      3. Pfizer Inc.
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      4. Janssen Global Services, LLC (Johnson & Johnson Services, Inc.)
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      5. AbbVie Inc.
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      6. AstraZeneca
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      7. H. Lundbeck A/S
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      8. Sandoz International GmbH (Novartis AG)
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trend
  4. Key Insights
    1. Prevalence of Treatment-Resistant Depression in the U.S., 2022
    2. Overview of Current Advances in R&D for Antipsychotic Drugs
    3. Pipeline Analysis of Treatment-Resistant Depression Drugs
    4. Key Industry Developments
    5. Impact of COVID-19 on Market
  5. U.S. Treatment-Resistant Depression Treatment Market Analysis, Insights and Forecast, 2019-2030
    1. Market Analysis, Insights and Forecast – By Drug Type
      1. N-Methyl-D-aspartate (NMDA)
      2. Antidepressants
      3. Antipsychotics
      4. Others
    2. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Drug Stores & Retail Pharmacies
      3. Online Pharmacies
  6. Competitive Analysis
    1. U.S. Market Share Analysis (2022)
    2. Company Profiles
      1. Eli Lilly and Company
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      2. GlaxoSmithKline
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      3. Pfizer Inc.
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      4. Janssen Global Services, LLC (Johnson & Johnson Services, Inc.)
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      5. AbbVie Inc.
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      6. AstraZeneca
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      7. H. Lundbeck A/S
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      8. Sandoz International GmbH (Novartis AG)
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
Read Less

Figure 1: U.S. Treatment-Resistant Depression Treatment Market Revenue Breakdown (USD million, %) by Drug Class, 2022 & 2030

Figure 2: U.S. Treatment-Resistant Depression Treatment Market Value Share (%), by Drug Type, 2022 & 2030

Figure 3: U.S. Treatment-Resistant Depression Treatment Market Value Share (%), by Distribution Channel, 2022 & 2030

Figure 4: U.S. Treatment-Resistant Depression Treatment Market Share (%), By Company, 2022

Table 1: U.S. Treatment-Resistant Depression Treatment Market Revenue (USD million) Forecast, by Drug Type, 2019-2030

Table 2: U.S. Treatment-Resistant Depression Treatment Market Revenue (USD million) Forecast, by Distribution Channel, 2019-2030

Table 3: U.S. Treatment-Resistant Depression Treatment Market Revenue (USD million) Forecast, by Region, 2019-2030

U.S. Treatment-resistant Depression Treatment Market
  • 2019-2030
  • 2022
  • 2019-2021
  • 60
Download Free Sample

    man icon
    Mail icon
    Captcha refresh
Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann

Related Reports